Verapamil SR

Phase 2Small molecule

MMedical University of Graz

Verapamil SR is one of 35 small molecule programs targeting Type 1 Diabetes. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 DiabetesActive, not recruiting

Type 1 DiabetesPhase 2

Active, not recruiting

Competition

Competitive Landscape

77 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

18 2

Mounjaro

Eli Lilly

Approved

6 3

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 4

Alka-Seltzer

AAbbott

Approved

1 5

Ozempic

Novo Nordisk

Phase 3

7 6

Stelara

Johnson & Johnson

Phase 3

1 7

Inpefa

LLexicon Pharmaceuticals

Phase 3

5 8

Tricor

JJagotec

Phase 3

2 9

Atorvastatin Calcium

Merck & Co.

Phase 3

1 10

Diamox

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes1 trial

Verapamil SR in Adults With Type 1 Diabetes

Active, not recruiting·MMedical University of Graz·Phase 2·NCT04545151·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Verapamil SR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Verapamil SR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Verapamil SR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Graz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMedical University of Graz

Verapamil SR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes1 trial

References

Drug Info

Quick Facts

Related News